Neurocrine Biosciences (NBIX) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Stifel on Neurocrine Bio. (NBIX): 'Really Nice Ingrezza Quarter, Guidance Starting to Look Potentially Conservative'
May 4, 2022 10:25 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $136.00 price target on Neurocrine Bio. (NASDAQ: NBIX).
The analyst comments "We are reiterating our Buy rating on NBIX on a strong quarter for Ingrezza ($303MM) which beat our estimate and consensus by ~$23MM and... More
Raymond James on Neurocrine Bio. (NBIX): 'Solid Beat for Ingrezza; Well Positioned Moving Forward'
May 4, 2022 10:24 AM EDTRaymond James analyst Danielle Brill reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX).
The analyst comments "Ingrezza 1Q revenues solidly beat expectations, and FY22 guidance was rea"irmed. Lighter seasonal payer headwinds and enhanced compliance helped contribute to the strong Ingrezza revenue... More
